Epigenomics AG (ECX) | WebDisclosure

Switch to English

8296	Sociétés
114905	Mots-clés
55332	Articles
62461	Communiqués

Accueil
Sociétés
Epigenomics AG

BRÈVE

publiée le 30/04/2024 à 15:05, il y a 6 mois 20 jours

Epigenomics AG annonce le départ de Jens Ravens, membre du conseil d'administration

Transfert D'actifs Conseil Exécutif Restructuration D'entreprise Epigénomique AG Jens Corbeaux
BRÈVE

publiée le 30/04/2024 à 15:05, il y a 6 mois 20 jours

Epigenomics AG Announces Departure of Executive Board Member Jens Ravens

Executive Board Epigenomics AG Asset Transfer Corporate Restructuring Jens Ravens
COMMUNIQUÉ DE PRESSE

publié le 30/04/2024 à 15:00, il y a 6 mois 20 jours

Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024
Epigenomics AG Executive Board member Jens Ravens leaves the Company on April 30, 2024, due to successful asset transfer to New Day Diagnostics LLC. Jens Ravens played a key role in securing the company's future

Executive Board Epigenomics AG Asset Transfer Jens Ravens New Day Diagnostics LLC
BRÈVE

publiée le 14/03/2024 à 08:05, il y a 8 mois 7 jours

Epigenomics AG annonce ses résultats financiers pour 2023 et sa restructuration stratégique

Résultats Financiers Restructuration Epigénomique AG Société D'investissements Détection Du Cancer
BRÈVE

publiée le 14/03/2024 à 08:05, il y a 8 mois 7 jours

Epigenomics AG Announces 2023 Financial Results and Strategic Restructuring

Financial Results Restructuring Epigenomics AG Holding Company Cancer Detection
COMMUNIQUÉ DE PRESSE

publié le 14/03/2024 à 08:00, il y a 8 mois 7 jours

Epigenomics AG publishes financial results for fiscal year 2023
Epigenomics AG reports financial results for fiscal year 2023 including key figures and operational developments. The company undergoes restructuring measures and enters into agreements to ensure future sustainability

Financial Results Epigenomics AG Fiscal Year 2023 Restructuring Measures Business Outlook
COMMUNIQUÉ DE PRESSE

publié le 15/02/2024 à 10:00, il y a 9 mois 6 jours

Epigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet
Jochen Hummel appointed to Epigenomics AG's Supervisory Board to replace Heikki Lanckriet. Appointment effective Feb 5, 2024, enriching the Board with tax expertise

Supervisory Board Epigenomics AG Jochen Hummel Heikki Lanckriet Corporate Announcement
COMMUNIQUÉ DE PRESSE

publié le 31/01/2024 à 15:30, il y a 9 mois 20 jours

Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Board
Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Board, bringing extensive management experience and finance expertise

Executive Board Supervisory Board Epigenomics AG Hansjörg Plaggemars Finance Expertise
COMMUNIQUÉ DE PRESSE

publié le 26/01/2024 à 13:16, il y a 9 mois 26 jours

Epigenomics AG: Resignation of Supervisory Board Member Dr Heikki Lanckriet (PhD)
Dr. Heikki Lanckriet (PhD) resigns as a member of Epigenomics AG's Supervisory Board effective February 22, 2024. The board will seek a suitable successor as per statutory provisions.

Resignation Supervisory Board Epigenomics AG Dr. Heikki Lanckriet Corporate News
COMMUNIQUÉ DE PRESSE

publié le 30/10/2023 à 15:49, il y a 1 année

EQS-Adhoc: Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024

Les Echos

Publié le 21/11/2024 à 06:58, il y a 7 heures 10 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 7 heures 10 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 7 heures 10 minutes

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 18 heures 1 minute

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 18 heures 48 minutes

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 21/11/2024 à 13:30, il y a 38 minutes

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Publié le 21/11/2024 à 13:30, il y a 38 minutes

Datametrex Secures Additional P.O. Approx $250K for IT Services
Publié le 21/11/2024 à 13:00, il y a 1 heure 8 minutes

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Publié le 21/11/2024 à 13:00, il y a 1 heure 8 minutes

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Publié le 21/11/2024 à 13:00, il y a 1 heure 8 minutes

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

Voir tout ACCESSWIRE

EQS Group

Publié le 21/11/2024 à 13:41, il y a 27 minutes

Original-Research: Pentixapharm Holding AG (von BankM AG): Kaufen
Publié le 21/11/2024 à 13:15, il y a 53 minutes

NOTICE OF ANNUAL GENERAL MEETING
Publié le 21/11/2024 à 12:35, il y a 1 heure 33 minutes

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Publié le 21/11/2024 à 12:15, il y a 1 heure 53 minutes

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Publié le 21/11/2024 à 12:06, il y a 2 heures 2 minutes

IVU AG publishes Quarterly Report Q3-2024